These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
701 related articles for article (PubMed ID: 15455293)
21. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Skinner MA; Wells SA Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335 [TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid carcinoma: state of the art. Favia G; Iacobone M G Chir; 2005; 26(11-12):405-9. PubMed ID: 16472416 [TBL] [Abstract][Full Text] [Related]
23. [Neural crest and multiple endocrinopathies]. Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721 [TBL] [Abstract][Full Text] [Related]
24. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation? Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011 [TBL] [Abstract][Full Text] [Related]
25. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Kameyama K; Okinaga H; Takami H Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413 [TBL] [Abstract][Full Text] [Related]
27. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. Fialkowski EA; DeBenedetti MK; Moley JF; Bachrach B J Pediatr Surg; 2008 Jan; 43(1):188-90. PubMed ID: 18206480 [TBL] [Abstract][Full Text] [Related]
28. RET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management. Mukherjee S; Zakalik D Clin Genet; 2011 Jan; 79(1):1-16. PubMed ID: 20497437 [TBL] [Abstract][Full Text] [Related]
29. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC. Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716 [TBL] [Abstract][Full Text] [Related]
30. [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II]. Engelbach M; Kunt T; Kann P; Manfras B; Hankeln T; Forst T; Pfützner A; Heerdt S; Walgenbach S; Lehnert H; Beyer J Dtsch Med Wochenschr; 2000 Jan; 125(3):37-44. PubMed ID: 10681997 [TBL] [Abstract][Full Text] [Related]
31. Molecular diagnosis of multiple endocrine neoplasia Type 2. Bugalho MJ; Domingues R; Sobrinho L Expert Rev Mol Diagn; 2003 Nov; 3(6):769-79. PubMed ID: 14628904 [TBL] [Abstract][Full Text] [Related]
32. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report. Menon MM; Simha MR Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654 [TBL] [Abstract][Full Text] [Related]
33. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers]. Sansó G; Domené HM; Iorcansky S; Barontini M Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252 [TBL] [Abstract][Full Text] [Related]
34. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022 [TBL] [Abstract][Full Text] [Related]
35. [Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers]. Høie J; Heimdal K; Nesland JM; Børmer O Tidsskr Nor Laegeforen; 2000 Nov; 120(27):3249-52. PubMed ID: 11187163 [TBL] [Abstract][Full Text] [Related]
36. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. Heshmati HM; Hofbauer LC Eur J Endocrinol; 1997 Dec; 137(6):572-8. PubMed ID: 9437218 [No Abstract] [Full Text] [Related]
37. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature]. de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023 [TBL] [Abstract][Full Text] [Related]
38. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714 [TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Alvandi E; Akrami SM; Chiani M; Hedayati M; Nayer BN; Tehrani MR; Nakhjavani M; Pedram M Thyroid; 2011 Apr; 21(4):373-82. PubMed ID: 21309721 [TBL] [Abstract][Full Text] [Related]
40. Management of patients with hereditary medullary thyroid carcinoma. Fitze G Eur J Pediatr Surg; 2004 Dec; 14(6):375-83. PubMed ID: 15630638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]